The optimal treatment for patients with localized muscle-infiltrating urothelial carcinoma (Jewett stage B or T2-T3a of the TNM classification, UICC 1992) continues to be a controversy. The present study analyzed the survival rate in patients with stage T2-T3a bladder cancer who had been treated...
Bloom HJ,Hendry WF,Wallace DM,et al.Treatment of T3 bladder cancer:controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. British Journal of Urology . 1982Bloom HJG, Hendry WF, Wallace DM, Skeet RG. Treatment of T3 bladder cancer; controlled trial of ...
Intravesical bacille Calmette-Guérin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up Objectives. To assess the long-term results of intravesical bacille Calmette-Gu茅rin (BCG) treatment for Stage T1 grade 3 (T1G3) transitional cell carcinom... Rodolfo,Hurle,and,... - 《Ur...
- 《Cancer Research》 被引量: 0发表: 2018年 Performance of ceramic laminate veneers with immediate dentine sealing: An 11 year prospective clinical trial Objective. In this prospective clinical trial the survival, success rate and patient satisfaction of ceramic laminate veneers with special interest...
Bladder cancer is one of the most common malignancies involving the urinary system of about 1.65 million cases worldwide. To attain the 25 by 25 goal set by the World Health Organization (25% reduction in non-communicable diseases between 2015 and 2025),
Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer. Bladder Cancer. 2017;3:259–67. Article PubMed PubMed Central Google Scholar Griss J, Bauer W, Wagner C, Simon M, Chen MY, Grabmeier-Pfistershammer K, Maurer-Granofszky M, Roka F, Penz T, Bock C, ...
4f), and M stage (Fig. 4g) were significantly correlated with the risk score. In conclusion, our risk assessment model can serve as an independent prognostic factor for bladder cancer. Correlation analysis of tumour-infiltrating immune cells and immunosuppressive molecules using a risk assessment ...
Guidelines Version 2.2012 Guidelines Index Bladder Cancer TOC Bladder Cancer Discussion CLINICAL INITIAL PRESUMPTIVE WORKUP PRIMARY EVALUATION/ cTac See BL-2 PRESENTATION EVALUATION CLINICAL SURGICAL TREATMENT STAGE cT1c See BL-2 •Examination under •Imaging of upper anesthesia (bi ) Papillary cT2c...
Bladder cancer is an aggressive and lethal disease. Even when presenting as localized muscle-invasive disease, the 5-year survival rate is about 70%, and the recurrence rate after radical cystectomy is approximately 50%. Neoadjuvant chemotherapy (NAC) has the potential to downstage the primary tum...
and validation data sets (Table3). The sensitivity and specificity of the selected 37 metabolites were also determined and all metabolites disclosed sensitivity and specificity greater than 74 and 62%, respectively S3, Supplementary information2). Comparison of the three groups of cancer stage (pT1...